12 Month Price Forecast For FNA
Distance to FNA Price Forecasts
FNA Price Momentum
๐ค Considering Paragon 28 (FNA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 2:44 PM UTC
FNA Analyst Ratings & Price Targets
Based on our analysis of 10 Wall Street analysts, FNA has a neutral consensus with a median price target of $13.00 (ranging from $12.00 to $20.00). Currently trading at $13.06, the median forecast implies a -0.5% downside. This outlook is supported by 2 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Turkaly at JMP Securities, projecting a 53.1% upside. Conversely, the most conservative target is provided by Matt O'Brien at Piper Sandler, suggesting a 8.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FNA Analyst Consensus
FNA Price Target Range
Latest FNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FNA.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 30, 2025 | Stephens & Co. | Mason Carrico | Equal-Weight | Downgrade | $13.00 |
Jan 29, 2025 | William Blair | Brandon Vazquez | Market Perform | Downgrade | $0.00 |
Jan 29, 2025 | Needham | Mike Matson | Hold | Downgrade | $13.00 |
Jan 29, 2025 | Canaccord Genuity | Kyle Rose | Hold | Downgrade | $0.00 |
Jan 13, 2025 | Needham | Buy | Reiterates | $0.00 | |
Nov 13, 2024 | Needham | Mike Matson | Buy | Maintains | $13.00 |
Nov 13, 2024 | Canaccord Genuity | Kyle Rose | Buy | Maintains | $15.00 |
Aug 9, 2024 | Needham | Mike Matson | Buy | Maintains | $11.00 |
Aug 9, 2024 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $12.00 |
May 9, 2024 | JMP Securities | David Turkaly | Market Outperform | Maintains | $20.00 |
May 9, 2024 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $15.00 |
May 9, 2024 | Needham | Mike Matson | Buy | Maintains | $14.00 |
Apr 5, 2024 | Stephens & Co. | George Sellers | Overweight | Reiterates | $18.00 |
Apr 4, 2024 | Needham | Mike Matson | Buy | Reiterates | $17.00 |
Mar 28, 2024 | Needham | Mike Matson | Buy | Reiterates | $17.00 |
Mar 27, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $18.00 |
Mar 1, 2024 | Needham | Mike Matson | Buy | Maintains | $17.00 |
Nov 8, 2023 | Needham | Mike Matson | Buy | Maintains | $14.00 |
Sep 29, 2023 | William Blair | Brandon Vazquez | Outperform | Initiates | $0.00 |
Aug 3, 2023 | Needham | Mike Matson | Buy | Reiterates | $24.00 |
Stocks Similar to Paragon 28, Inc.
The following stocks are similar to Paragon 28 based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Paragon 28, Inc. (FNA) Financial Data
Paragon 28, Inc. has a market capitalization of $1.10B with a P/E ratio of -18.7x. The company generates $245.00M in trailing twelve-month revenue with a -22.9% profit margin.
Revenue growth is +18.1% quarter-over-quarter, while maintaining an operating margin of -13.6% and return on equity of -33.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Paragon 28, Inc. (FNA) Company Overview
About Paragon 28, Inc.
Develops foot and ankle surgical systems.
The company generates revenue by developing, distributing, and selling a wide range of surgical systems and technologies focused on foot and ankle procedures. Its product offerings include plating systems, precision guide technology, and various orthobiologics, which are marketed to hospitals and ambulatory surgery centers through a network of sales representatives and distributors.
Founded in 2010 and headquartered in Englewood, Colorado, Paragon 28, Inc. operates both domestically and internationally, targeting a specialized niche in the orthopedic market. The companyโs innovation in surgical systems, including total ankle replacements and advanced fixation methods, positions it well to meet growing demand in orthopedic surgeries.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
574
CEO
Mr. Albert DaCosta
Country
United States
IPO Year
2021
Website
paragon28.comParagon 28, Inc. (FNA) Latest News & Analysis
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Paragon 28, Inc. (NYSE:FNA) investors who bought securities before May 5, 2023. More info is available at bgandg.com/FNA.
Investigations into Paragon 28 may indicate potential legal issues or financial irregularities, which could impact stock performance and investor sentiment.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Paragon 28, Inc. (NYSE:FNA) investors who bought securities before May 5, 2023. Visit bgandg.com/FNA for more info.
The investigation into Paragon 28 may indicate potential legal issues or financial misconduct, which could negatively impact the company's stock value and investor confidence.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors who purchased Paragon 28, Inc. (NYSE:FNA) securities before May 5, 2023.
The investigation into Paragon 28 may indicate potential legal issues or financial instability, which could affect stock performance and investor sentiment.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA and TGI on Behalf of Shareholders
2 days agoHalper Sadeh LLC is investigating Paragon 28, Inc. for potential securities law violations related to its sale to Zimmer Biomet for $13.00 per share, plus a contingent value right of up to $1.00.
The investigation into Paragon 28's sale highlights potential legal issues that could impact shareholder value and the future performance of the stock, influencing investor sentiment and decisions.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Paragon 28, Inc. (NYSE:FNA) investors who bought shares before May 5, 2023. More info is available at bgandg.com/FNA.
The investigation into Paragon 28 may indicate potential legal issues or financial irregularities, which could impact the company's stock performance and investor sentiment.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Paragon 28, Inc. (NYSE:FNA) who purchased securities before May 5, 2023. More info at bgandg.com/FNA.
Legal investigations can signal potential liabilities or wrongdoing, impacting Paragon 28's stock price and investor sentiment, which may lead to volatility for those holding shares.
Frequently Asked Questions About FNA Stock
What is Paragon 28, Inc.'s (FNA) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Paragon 28, Inc. (FNA) has a median price target of $13.00. The highest price target is $20.00 and the lowest is $12.00.
Is FNA stock a good investment in 2025?
According to current analyst ratings, FNA has 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for FNA stock?
Wall Street analysts predict FNA stock could reach $13.00 in the next 12 months. This represents a -0.5% decrease from the current price of $13.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Paragon 28, Inc.'s business model?
The company generates revenue by developing, distributing, and selling a wide range of surgical systems and technologies focused on foot and ankle procedures. Its product offerings include plating systems, precision guide technology, and various orthobiologics, which are marketed to hospitals and ambulatory surgery centers through a network of sales representatives and distributors.
What is the highest forecasted price for FNA Paragon 28, Inc.?
The highest price target for FNA is $20.00 from David Turkaly at JMP Securities, which represents a 53.1% increase from the current price of $13.06.
What is the lowest forecasted price for FNA Paragon 28, Inc.?
The lowest price target for FNA is $12.00 from Matt O'Brien at Piper Sandler, which represents a -8.1% decrease from the current price of $13.06.
What is the overall FNA consensus from analysts for Paragon 28, Inc.?
The overall analyst consensus for FNA is neutral. Out of 10 Wall Street analysts, 2 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are FNA stock price projections?
Stock price projections, including those for Paragon 28, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.